WALTHAM, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of two abstracts at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held from November 8–12, 2022, at the Boston Convention and Exhibition Center in Boston, MA.
Title: Multiplexed TCR-T cell therapy targeting MAGEA1 and PRAME to enhance TCR-T therapeutic efficacy
Authors: Antoine J. Boudot, Jenny Tadros, Tary Traore, Maytal Bowman, Victor Ospina, Nancy Nabilsi, Mollie M Jurewicz, Elizabeth M Hall, Qikai Xu, Yifan Wang, Cagan Gurer, Gavin MacBeath
Abstract Number: 389
Date & Time: Thursday, November 10, 2022, from 9:00am-9:00pm ET
Location: Exhibition Hall C
Title: Discovery of TSC-203-A02: A PRAME-specific TCR-T cell therapy candidate for the treatment of solid tumors
Authors: Mollie M Jurewicz, Elizabeth M Hall, Alexandra L Luther, Kimberly M Cirelli, Vivin Karthik, Kenneth L Jahan, Tary Traore, Maytal Bowman, Victor Ospina, Sonal Jangalwe, Shubhangi Kamalia, Sadie Lee, Daniel C Pollacksmith, Sida Liao, Amy Virbasius, Kristen Murray, Jillian L Oliveira, Lisa Nip, Christina E Lam, Livio Dukaj, Danielle Ramsdell, Jin He, Joel W Sher, Ribhu Nayar, Qikai Xu, Yifan Wang, Antoine Boudot, Cagan Gurer, Gavin MacBeath
Abstract Number: 182
Date & Time: Friday, November 11, 2022, from 9:00am-8:30pm ET
Location: Exhibition Hall C
About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types in order to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the Company’s current and future research and development plans or expectations, the structure, timing and success of the Company’s planned preclinical development and clinical trials, and the Company’s goals, strategy, and focus. TScan intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “plan,” “on track,” or similar expressions or the negative of those terms. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. The express or implied forward-looking statements included in this release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of TScan’s TCR-T therapy candidates; TScan’s expectations regarding its preclinical studies being predictive of clinical trial results; the timing of the initiation, progress and expected results of TScan’s preclinical studies, clinical trials and its research and development programs; TScan’s plans relating to developing and commercializing its TCR-T therapy candidates, if approved, including sales strategy; estimates of the size of the addressable market for TScan’s TCR-T therapy candidates; TScan’s manufacturing capabilities and the scalable nature of its manufacturing process; TScan’s estimates regarding expenses, future milestone payments and revenue, capital requirements and needs for additional financing; TScan’s expectations regarding competition; TScan’s anticipated growth strategies; TScan’s ability to attract or retain key personnel; TScan’s ability to establish and maintain development partnerships and collaborations; TScan’s expectations regarding federal, state and foreign regulatory requirements; TScan’s ability to obtain and maintain intellectual property protection for its proprietary platform technology and our product candidates; the sufficiency of TScan’s existing capital resources to fund its future operating expenses and capital expenditure requirements; and the effect of the COVID-19 pandemic, including mitigation efforts and political, economic, legal and social effects, on any of the foregoing or other aspects of TScan’s business or operations; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of TScan’s most recent Annual Report on Form 10-K and any other filings that TScan has made or may make with the SEC in the future. Any forward-looking statements contained in this release represent TScan’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, TScan explicitly disclaims any obligation to update any forward-looking statements.
TScan Therapeutics, Inc.
VP, Investor Relations
LifeSci Advisors, LLC